Analyst Ratings For Caladrius Biosciences (NASDAQ:CLBS)
Today, HC Wainwright reiterated its Buy rating on Caladrius Biosciences (NASDAQ:CLBS) with a price target of $7.00.
There are 2 buy ratings on the stock.
The current consensus rating on Caladrius Biosciences (NASDAQ:CLBS) is Buy (Score: 3.00) with a consensus target price of $6.75 per share, a potential 66.26% upside.
Some recent analyst ratings include
- 7/21/2017-HC Wainwright Reiterated Rating of Buy.
- 11/9/2016-Chardan Capital Reiterated Rating of Buy.
- 5/14/2016-Maxim Group Reiterated Rating of Hold.
- 4/30/2016-Rodman & Renshaw Upgrade from a “Buy” rating to a “” rating.
- 1/26/2016-Aegis Reiterated Rating of Buy.
- 9/24/2015-WBB Securities Reiterated Rating of Buy.
- 8/7/2015-Benchmark Co. was Downgraded by analysts at Benchmark Co. from a “Buy ” rating to a ” Hold” rating. They now have a $2.00 price target on the stock, up previously from $12.00 .
Recent Insider Trading Activity For Caladrius Biosciences (NASDAQ:CLBS)
Caladrius Biosciences (NASDAQ:CLBS) has insider ownership of 13.10% and institutional ownership of 5.55%.
- On 2/7/2017 Eric Wei, Director, sold 6,575 with an average share price of $4.77 per share and the total transaction amounting to $31,362.75. View SEC Filing
- On 2/6/2017 Eric Wei, Director, sold 8,425 with an average share price of $4.61 per share and the total transaction amounting to $38,839.25. View SEC Filing
- On 7/1/2016 Eric Wei, Director, sold 87,500 with an average share price of $0.60 per share and the total transaction amounting to $52,500.00. View SEC Filing
- On 6/24/2016 Eric Wei, Director, sold 22,698 with an average share price of $0.55 per share and the total transaction amounting to $12,483.90. View SEC Filing
- On 8/17/2015 David J Mazzo, CEO, bought 20,000 with an average share price of $1.40 per share and the total transaction amounting to $28,000.00. View SEC Filing
- On 8/11/2015 Robert S Vaters, CFO, bought 81,000 with an average share price of $1.24 per share and the total transaction amounting to $100,440.00. View SEC Filing
- On 12/9/2014 Steven S Myers, Director, bought 20,000 with an average share price of $3.56 per share and the total transaction amounting to $71,200.00. View SEC Filing
Recent Trading Activity for Caladrius Biosciences (NASDAQ:CLBS)
Shares of Caladrius Biosciences closed the previous trading session at 4.06 up +0.02 0.50% with 14,859 shares trading hands.